Article

Pfizer group to combine Pharmacia products

New York-Pfizer Inc. is launching a new business group to combine its products with those gained with the April acquisition of Pharmacia Corp.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Part 6: Biggest innovations in ophthalmology in 50 years
Part 6: Biggest innovations in ophthalmology in 50 years
Part 5: Biggest innovations in ophthalmology in 50 years
Part 5: Biggest innovations in ophthalmology in 50 years
Part 4: Biggest innovations in ophthalmology in 50 years
Part 4: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
Part 3: Biggest innovations in ophthalmology in 50 years
Part 3: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
Part 2: Biggest innovations in ophthalmology in 50 years
Part 2: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Related Content
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy
April 11th 2025

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Pykus Therapeutics completes enrollment in trial evaluating PYK-2101
April 11th 2025

Pykus Therapeutics completes enrollment in trial evaluating PYK-2101

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Opthea to lay off approximately 65% of company
April 10th 2025

Opthea to lay off approximately 65% of company

(Image credit: AdobeStock/©rh2010)
April 10th 2025

Presbyopia treatment success begins with patient-centered care

© 2025 MJH Life Sciences

All rights reserved.